Opuviz™ (aflibercept-yszy) and Yesafili™ (aflibercept-jbvf)– New first-time interchangeable biosimilar approvals
May 20, 2024 - The FDA announced the approval of Samsung Bioepis/Biogen’s Opuviz (aflibercept-yszy) and Biocon’s Yesafili (aflibercept-jbvf), biosimilar and interchangeable to Regeneron’s Eylea (aflibercept).